Lilly sues Barcelona’s Galenicum in the US over Mounjaro’s patents — the generic race for the decade’s biggest prize has a Spanish runner
The Hispano-Luso Report
Being sued by Eli Lilly is, in the strange grammar of American pharmaceutical law, a form of arrival. Lilly has filed suit in the United States against Galenicum, the Barcelona pharmaceutical group, for infringing the patents on Mounjaro — tirzepatide, the diabetes-and-obesity medicine that has become the most valuable drug franchise on earth. The Spanish press reports the lawsuit; this Report reads the mechanism behind it, because the mechanism is the story: a company does not get sued over Mounjaro’s patents by accident. It gets sued because it filed to make a generic — and declared, in the filing, that Lilly’s patents would not stop it. A Spanish firm has taken on the world’s biggest drug. The lawsuit is Lilly’s obligatory reply.
The mechanism, explained plainly
American law runs generic competition as a formal duel. A challenger files an application to sell a copy of a patented drug and attaches a certification — the famous “Paragraph IV” — asserting the patents are invalid or not infringed. The originator then has a statutory window to sue, and nearly always does: the lawsuit freezes the generic for a period and moves the fight to a federal court, where the patents are tested. Mounjaro became eligible for such challenges only this May, when the drug’s initial exclusivity period opened; the litigation ledger around it already counts more than a dozen cases, which tells the reader two things at once — that Galenicum is among the challengers rather than alone, and that the queue formed the instant the door opened. The stake is dated: analysts place the earliest plausible generic entry around late 2028, with the estate’s stronger patents running into the 2030s. The duel’s historical record favours challengers more often than not — and a settlement, with a licensed entry date, is the commonest ending of all.
The prize, sized
The numbers explain the queue. Tirzepatide — sold as Mounjaro for diabetes and Zepbound for obesity — earned Lilly around $16 billion in 2024 and has grown at a pace that put it on course for the summit of the global sales table: the drug that turned a hundred-year-old Indianapolis company into the most valuable healthcare business in history, on the strength of a single molecule the world cannot buy enough of. A generic of it, whenever it arrives, is the largest prize the copy-drug industry has ever contemplated. Every credible generics house on earth wants a place in the line. One of them, it turns out, is Catalan.
The Spanish runner
Galenicum is a Barcelona group of the type Catalonia’s pharmaceutical cluster produces — active-ingredient and generic-development businesses that supply the world’s copy-drug makers with the chemistry and the dossiers behind their launches — and this Report notes it as the latest specimen of a sector the masthead has under-covered: Catalonia’s pharma corridor (Grifols in plasma, Almirall and Esteve in specialty medicines, a constellation of API and generics firms behind them) is one of Europe’s densest life-sciences clusters and a genuine anglosphere exporter, its plants and filings pointed at the US market above all. A Catalan firm in the Mounjaro queue is the cluster doing what it exists to do, at the largest scale it has ever attempted.
The honest ledger
The counterweights, at full weight. A lawsuit is the first round, not a verdict — these cases run years, and the likeliest outcome is a negotiated entry date rather than a courtroom win. Galenicum is one runner among many — the title says “takes on,” which is true; it does not say “alone,” which would not be. Lilly’s estate is formidable — the compound patent alone runs deep into the next decade, and the challengers’ historical win rate applies to weaker estates than this one. The details are the Spanish press’s — the filing’s specifics, the patents cited, Galenicum’s own account, all graded as they publish. And the fifth check hums in reverse: the originator’s suit is a legal reflex, not a judgment on the challenger’s chances — being sued proves entry to the race, nothing more.
The scoreboard
Still, mark the entry: the world’s most valuable drug has a Spanish challenger in a US federal court, in a race whose finish line is dated and whose prize has no precedent. The watch-list takes the docket (the patents at issue, the court, the calendar), any settlement, and the cluster’s next filings — because where one Catalan firm queues for the decade’s biggest generic, others tend to follow. The biggest drug on earth just learned the name of a Barcelona company. Watch the docket.
The Hispano-Luso Report tracks the Spanish- and Portuguese-speaking business news that English-speaking coverage overlooks — analysed beyond the English-language headlines. Sources: elEconomista, Lilly filings and results, US patent and litigation data.
